SoundHealth Launches Android App for Its FDA-Approved SONU Band
SoundHealth Launches Android App for Its FDA-Approved SONU Band
Share
Built to work seamlessly with the band, the app leverages proprietary AI to analyze 3D facial scans in conjunction with symptom data and CT imaging to deliver precise, therapeutic-grade treatments for sinus and allergy-related conditions.
'We are thrilled to bring the SONU Band to Android users now,' said Dr. Paramesh Gopi, founder and CEO of SoundHealth. 'Our Android app is a first of its kind, and this launch expands access to drug-free relief to millions of people suffering from allergies and sinus issues.'
The SONU app scans the patient's face using a smartphone and creates a digital map of their sinuses, calculating their optimal resonant frequencies. Following the initial one-time scan, the patient simply places the SONU Band around their head, turns it on and the band delivers frequencies tailored to the patient.
The band opens airways naturally to reduce congestion and promote easy breathing, without drugs or steroids. Providing relief in just 15 minutes, SONU is recommended by over 1,000 doctors and dentists across the country.
SONU is the only FDA-approved device equivalent to or better than the leading nasal steroid spray, calming down symptoms of allergies, inflammation and congestion. It uses acoustic vibrational energy to provide personalized relief, reducing swelling, opening nasal passages and draining healthy mucus.
Over 80 percent of SONU patients report improvement in their nasal symptoms, representing a new category of safe and rapid relief therapies for nasal congestion. The SONU Band also recently received FDA approval for pediatric use for children over 12 years of age, giving families a safe alternative to pharmaceuticals.
SONU is convenient, user-friendly and pleasant to use for patients. For more information, please visit https://soundhealth.life/.
About SoundHealth
SoundHealth is a medical technology company that harnesses the power of artificial intelligence and medical science to improve respiratory and mental health. The SoundHealth team consists of experienced medical professionals, data scientists and engineers who are passionate about improving healthcare. visit https://soundhealth.life.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
34 minutes ago
- Business Wire
Feinstein Institutes Explores Noninvasive Bioelectronic Medicine to Manage Insulin, Blood Sugar After Surgery
MANHASSET, N.Y.--(BUSINESS WIRE)--Scientists and engineers at Northwell Health's Feinstein Institutes for Medical Research conduct bioelectronic medicine research to treat disease and injury, and recently found that focused ultrasound (FUS) has potential to manage high blood sugar after surgery. Published recently in Bioelectronic Medicine, an open-access journal distributed by the Feinstein Institutes and BMC, part of Springer Nature, used FUS to target a bundle of nerves – including branches from the vagus nerve – that communicate with organs like the liver and pancreas, essential for regulating glucose levels. The high-frequency sound waves of FUS activate neurons in the abdomen and alter neuronal signals that regulate production of insulin and other hormones. 'Managing disorders associated with high blood sugar, including hyperglycemia after surgery, is a critical challenge and current methods often fall short,' said Stavros Zanos, MD, PhD, professor in the Institute of Bioelectronic Medicine at the Feinstein Institutes and corresponding author of the paper. 'This research explores FUS, a new method for non-invasive neuromodulation, that may offer a potential pathway towards safer and more effective blood sugar control without the use of medications.' Using animal models, researchers targeted a nerve bundle called the superior mesenteric plexus (SMP) with FUS and measured its effects on insulin sensitivity, a key factor in how the body processes sugar. They found that FUS initially improved insulin sensitivity during surgery, however, when they checked the animals' blood sugar the day after, it was unexpectedly higher in the group that received FUS compared to the group that didn't. This suggests that while FUS can have immediate positive effects on insulin sensitivity, it might interfere with the body's natural ability to manage blood sugar in the hours following the stress of surgery. Next steps in this research will optimize the FUS treatment to attain long-lasting and beneficial effects on glucose metabolism after surgery and to better understand the biological mechanisms behind these effects. 'Dr. Zanos use of focused ultrasound is paving the way for new methods to stimulate the vagus nerve,' said Kevin J. Tracey, MD, president and CEO of the Feinstein Institutes and Karches Family Distinguished Chair in Medical Research. 'Since vagus nerve reflexes control blood glucose and insulin levels, I expect these results will generate widespread interest from scientists, physicians, and future patients.' Built on years of research in molecular mechanisms of disease and the link between the nervous and immune systems, researchers at the Feinstein Institutes discovered neural targets that can be activated or inhibited with neuromodulation devices, like vagus nerve implants, to control the body's immune response and inflammation. If inflammation is successfully controlled, diseases – such as arthritis, pulmonary hypertension, Crohn's disease, inflammatory bowel diseases, diabetes, cancer and autoimmune diseases – can be treated more effectively. Beyond inflammation, using novel brain-computer interfaces, Feinstein Institutes researchers developed techniques to bypass injuries of the nervous system so that people living with paralysis can regain sensation and use their limbs. By producing bioelectronic medicine knowledge, disease and injury, could one day be treated with our own nerves without costly and potentially harmful pharmaceuticals. Dr. Zanos, along with Sangeeta S. Chavan, PhD, professor in the Institute of Bioelectronic Medicine at the Feinstein Institutes, also led a successful first-in-human trial using FUS to reduce inflammation, targeting at the spleen in healthy participants and found it lowered levels of an inflammatory protein in the blood for over two hours About the Feinstein Institutes The Feinstein Institutes for Medical Research is the home of the research institutes of Northwell Health, the largest health care provider and private employer in New York State. Encompassing 50+ research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its six institutes of behavioral science, bioelectronic medicine, cancer, health system science, molecular medicine, and translational research. We are the global scientific leader in bioelectronic medicine – an innovative field of science that has the potential to revolutionize medicine. The Feinstein Institutes publishes two open-access, international peer-reviewed journals Molecular Medicine and Bioelectronic Medicine. Through the Elmezzi Graduate School of Molecular Medicine, we offer an accelerated PhD program. For more information about how we produce knowledge to cure disease, visit and follow us on LinkedIn.
Business Wire
2 hours ago
- Business Wire
Sinclair's Spotlight on America Wins National Press Club Award for Investigative Series Toxic Inaction
BALTIMORE--(BUSINESS WIRE)--Sinclair today announced that its Spotlight on America investigative reporting team has been honored with a prestigious National Press Club Award for the series Toxic Inaction, which uncovered alarming levels of toxic heavy metals in baby food and a lack of regulatory action to protect families. The award was presented in the Consumer Journalism category, which recognizes outstanding reporting that protects or informs consumers. The National Press Club Awards are among the most respected in journalism and are given annually to honor work that exemplifies the role of a free press in serving the public interest. Spotlight on America is Sinclair's national investigative reporting unit, producing in-depth, original accountability and enterprise reports and specials that air across Sinclair stations nationwide, as well as on The National News Desk. Toxic Inaction documented how government inaction has left millions of children vulnerable to exposure to toxic elements in products trusted by parents. The Spotlight on America team's year-long investigation prompted public awareness, legislative scrutiny, and renewed calls for federal reform. As a result of the reporting, Virginia and Maryland enacted laws that require baby food manufacturers to test their products for heavy metals and make those results available via a QR code on the label. In the spirit of Maryland's original bill, multiple other states are working on similar legislation. 'This recognition from the National Press Club underscores the power of investigative journalism to drive change and protect communities,' said Scott Livingston, Senior Vice President of News. 'Our Spotlight on America team is committed to shining a light on issues that matter and holding institutions accountable. We are incredibly proud of this work and the impact it continues to have.' The award-winning Spotlight on America team includes Nathan Aaron – Video Journalist, Matt Adams – Director, William Anderson – Executive Producer, Lisa Fletcher – National Investigative Correspondent, Mike Griffith – Video Journalist & Editor, Thomas Holt – Executive Producer, Aaron Hurley – Graphics Designer, and Andrea Nejman – Investigative Producer. 'We are tremendously proud of the Spotlight team and its continued work on this matter to pursue accountability and safety for children and families across the U.S.,' said Executive Producer Thomas Holt. 'Lisa Fletcher and Andrea Nejman have spearheaded this effort to inform the public and question authority, helping to facilitate meaningful change for our communities. This recognition of their dogged pursuits is well deserved.' About Sinclair: Sinclair, Inc. (Nasdaq: SBGI) is a diversified media company and a leading provider of local news and sports. The Company owns, operates and/or provides services to 185 television stations in 85 markets affiliated with all major broadcast networks; owns Tennis Channel, the premium destination for tennis enthusiasts; multicast networks CHARGE!, Comet, ROAR and The Nest; and the nation's largest streaming aggregator of local news content, NewsON. Sinclair's AMP Media produces a growing portfolio of digital content and original podcasts. Additional information about Sinclair can be found at Category: General
WebMD
3 hours ago
- WebMD
FDA OKs First-of-Its-Kind Lung Cancer Pill
approval to a first-of-its-kind pill for a type of lung cancer known as non-small-cell lung cancer (NSCLC). The drug, called sunvozertinib and sold as Zegfrovy, is for adults with advanced non-small-cell lung cancer (NSCLC). It works for people whose cancer has a certain genetic change, called an EGFR exon 20 insertion mutation. This drug is used when the cancer has gotten worse during or after chemotherapy. It is taken by mouth once a day, making it easier for patients to stick to their treatment, which can go on for a long time. The FDA also approved a test called the Oncomine Dx Express Test. This test helps find the EGFR exon 20 insertion mutation in people with NSCLC who might get Zegfrovy. The test gives results in just 24 hours, so doctors can find the mutation fast and start treatment sooner. NSCLC is the most common type of lung cancer, accounting for about 80% to 85% of all cases. Among these, EGFR exon 20 insertions are the third most common type of EGFR mutation and play a key role in helping cancer cells grow and spread. These cancers are often hard to treat because the mutations can vary from person to person, making it difficult to find effective treatment options. The FDA's approval was based on a clinical trial involving 85 people with advanced NSCLC and EGFR exon 20 insertion mutations whose cancer had worsened despite chemotherapy. They received oral Zegfrovy once daily until their cancer got worse or side effects became too severe. Results showed about 46% of them responded to the treatment, with benefits lasting for more than 11 months. Zegfrovy works by blocking bad EGFR proteins that help cancer cells grow. It is made to target many kinds of EGFR changes, including exon 20 insertion mutations, but it mostly leaves healthy cells alone. It may also help treat other rare EGFR changes and HER2 exon 20 insertion mutations. Ongoing approval may depend on confirming how well the drug works in further studies, according to a news release from Dizal, the drug's maker. In a statement, Pasi A. Jänne, MD, PhD, of the Dana-Farber Cancer Institute of Harvard Medical School and lead principal investigator of the clinical trial, said results from the study show that Zegfrovy works well for patients of different backgrounds. He noted that it's easy to take because it's just one pill a day, which helps people stick to their treatment – something that's really important as lung cancer care becomes more like managing a long-term illness. People taking Zegfrovy should know that the drug may cause serious side effects, including lung inflammation, stomach and skin problems, eye issues, and harm to an unborn baby.
